% | $
Quotes you view appear here for quick access.

BioTime, Inc. Message Board

  • btimnextmicrosoft btimnextmicrosoft Jun 16, 2014 4:54 PM Flag

    Little known fact: Biotime cancer therapy in development

    2011: BioTime, Inc. (NYSE Amex:BTX) today announced that it has acquired substantially all the assets of Cell Back Targeting, Inc. (CTI), a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine. The technology acquired from CTI uses peptides selected for their ability to adhere to diseased tissues. By coating or “painting” these peptides onto the surfaces of therapeutic cells using techniques that do not modify the cell physiology, CTI has produced tissue-specific and disease-specific cell modification agents with potential to take cell therapy products to a new level of performance. BioTime issued 261,959 common shares and paid $250,000 in cash to acquire the CTI assets.

    The acquired technology includes technology patented by CTI and an exclusive license to use technology invented by Dr. Erkki Ruoslahti’s group at the Sanford-Burnham Medical Research Institute (SBMRI) for use in cell therapy. The phage display peptide technology licensed from SBMRI holds promise for use in directing human cells derived from embryonic stem (hES) and induced pluripotent stem (iPS) cells to sites in the body where they can have therapeutic effect. BioTime will initially provide this technology to its majority owned subsidiary OncoCyte Corporation, for its R&D related to genetically modified hES-derived vascular progenitors designed to target and destroy malignant tumors.

    OncoCyte was formed in early 2009 to develop genetically modified stem cells capable of finding malignant tumors while carrying genes that can cause the destruction of the cancer cells. Since then, it has received $4.0 million in equity financing from private investors.

    “Our acquisition of the assets of CTI is indicative of our plan to assemble a core of stem cell and related manufacturing technologies capable of enabling our development of a wide array of therapeutic products in the emerging field of regenerative medicine,” said Michael D. West, Ph.D., President and Chief Executi

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Big pharma to partner with our cancer ip, will eventually rival Pfizer and their recent t-cell partnership. Question is who will be Biotimes partner? J&J, TEVA, Merck?

    • Dr. West recent cancer patent:
      Methods and Compositions for Targeting Progenitor Cell Lines
      US 20140099712 A1

      • 1 Reply to btimnextmicrosoft
      • Mandala CEO joined BTX last year! Another key acquisition:

        David Larocca joined ReCyte Therapeutics, Inc. as Vice President of Research and Development in September 2013. He previously founded Mandala Biosciences, LLC, where he served as Chief Executive Officer. At Mandala, he was Principal Investigator on several SBIR and CIRM awards aimed at improving therapeutic stem cell purity. Prior to Mandala, Dr. Larocca held positions at the Sanford Burnham Medical Research Institute, Advanced Cell Technology, Inc. and Selective Genetics, Inc. He is an inventor on 15 patents in the fields of immunotherapy, targeted gene therapy and regenerative medicine. Dr. Larocca holds a Ph.D. in Molecular and Cellular Biology from the University of Southern California and a B.S. in Biology from Ithaca College. He did his post-doctoral training at Harvard University.

    • And since this press release the company proceeded to lose more than half its value over the next 3 years.

2.82-0.06(-2.08%)May 5 4:00 PMEDT